Modified emulsion solvent evaporation method for fabricating core–shell microspheres

Xiao, Chao-Da; Shen, Xiangchun; Tao, Ling

doi:10.1016/j.ijpharm.2013.05.020

Cited by 47 publications

(27 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The solution of aspirin 0.040g/mL of chloroform was prepared and the resulting solution was mixed with the blends solution and homogenized it by stirring for 1 h. The homogenized solution of polymer blends and aspirin was added into PVA solution to fabricate the aspirin loaded microspheres. The solution containing obtained microspheres was centrifuged and microspheres were washed with deionized water and dried under vacuum [43].…”

Section: Drug Loading and In Vitro Drug Releasementioning

confidence: 99%

See 1 more Smart Citation

Sustained release of hydrophilic drug from polyphosphazenes/poly(methyl methacrylate) based microspheres and their degradation study

Akram

Khalid

et al. 2016

Materials Science and Engineering: C

View full text Add to dashboard Cite

Section: Drug Loading and In Vitro Drug Releasementioning

confidence: 99%

“…In addition, drug loading contents were determined by the UV spectroscopy method reported previously with little modification [43]. PPHOSs and aspirin show coinciding absorbance in UV region.…”

Section: Drug Loading and In Vitro Drug Releasementioning

confidence: 99%

Sustained release of hydrophilic drug from polyphosphazenes/poly(methyl methacrylate) based microspheres and their degradation study

Akram

Khalid

et al. 2016

Materials Science and Engineering: C

View full text Add to dashboard Cite

“…solvent extraction rate) can affect water inclusion inside PLGA microspheres, resulting in different microsphere inner structures [25,26]. As shown in Figure 2, the risperidone microspheres prepared using DCM as the solvent (i.e.…”

Section: Physicochemical Properties Of Risperidone Microspheresmentioning

confidence: 99%

In vitro-in vivo correlation of parenteral risperidone polymeric microspheres

Shen

Choi

et al. 2015

Journal of Controlled Release

View full text Add to dashboard Cite

The objective of the present study was to determine whether an in vitro-in vivo correlation (IVIVC) can be established for polymeric microspheres that are equivalent in formulation composition but prepared with different manufacturing processes. Risperidone was chosen as a model therapeutic and poly(lactic-co-glycolic acid) (PLGA) with similar molecular weight as that used in the commercial product Risperdal ® Consta ® was used to prepare risperidone microspheres. Various manufacturing processes were investigated to produce the risperidone microspheres with similar drug loading (approx. 37%) but distinctly different physicochemical properties (e.g. porosity, particle size and particle size distribution). In vitro release of the risperidone microspheres was investigated using different release testing methods (such as sampleand-separate and USP apparatus 4). In vivo pharmacokinetic profiles of the risperidone microsphere formulations following intramuscular administration were determined using a rabbit model. Furthermore, the obtained pharmacokinetic profiles were deconvoluted using the LooRiegelman method and the calculated in vivo release was compared with the in vitro release of these microspheres. Level A IVIVCs were established and validated for the compositionally equivalent risperidone microspheres based on the in vitro release data obtained using USP apparatus 4. The developed IVIVCs demonstrated good predictability and were robust. These results showed that the developed USP apparatus 4 method was capable of discriminating PLGA microspheres that are equivalent in formulation composition but with manufacturing differences and predicting their in vivo performance in the investigated animal model.

show abstract

“…33 Of the many papers in the drug delivery field that report the use of conventional and new nanocarriers to deliver a specific cargo to the targeted organ, only a few papers report the internal structure of these nanocarriers. 36,37 The development of robust nanocarriers for drug delivery purposes will require detailed internal characterization of these new carriers. It is essential to know whether the polymeric core is solid or hollow because the function of the particle's core depends on both internal and external physicochemical features.…”

Section: Recent Developments In Characterization Techniquesmentioning

confidence: 99%

Closing the gap: accelerating the translational process in nanomedicine by proposing standardized characterization techniques

Khorasani¹,

Weaver²,

Salvador-Morales³

2014

IJN

View full text Add to dashboard Cite

On the cusp of widespread permeation of nanomedicine, academia, industry, and government have invested substantial financial resources in developing new ways to better treat diseases. Materials have unique physical and chemical properties at the nanoscale compared with their bulk or small-molecule analogs. These unique properties have been greatly advantageous in providing innovative solutions for medical treatments at the bench level. However, nanomedicine research has not yet fully permeated the clinical setting because of several limitations. Among these limitations are the lack of universal standards for characterizing nanomaterials and the limited knowledge that we possess regarding the interactions between nanomaterials and biological entities such as proteins. In this review, we report on recent developments in the characterization of nanomaterials as well as the newest information about the interactions between nanomaterials and proteins in the human body. We propose a standard set of techniques for universal characterization of nanomaterials. We also address relevant regulatory issues involved in the translational process for the development of drug molecules and drug delivery systems. Adherence and refinement of a universal standard in nanomaterial characterization as well as the acquisition of a deeper understanding of nanomaterials and proteins will likely accelerate the use of nanomedicine in common practice to a great extent.

show abstract

Modified emulsion solvent evaporation method for fabricating core–shell microspheres

Cited by 47 publications

References 14 publications

Sustained release of hydrophilic drug from polyphosphazenes/poly(methyl methacrylate) based microspheres and their degradation study

Sustained release of hydrophilic drug from polyphosphazenes/poly(methyl methacrylate) based microspheres and their degradation study

In vitro-in vivo correlation of parenteral risperidone polymeric microspheres

Closing the gap: accelerating the translational process in nanomedicine by proposing standardized characterization techniques

Contact Info

Product

Resources

About